Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Update

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) was the recipient of a large decrease in short interest in August. As of August 31st, there was short interest totalling 2,270,000 shares, a decrease of 66.7% from the August 15th total of 6,810,000 shares. Based on an average trading volume of 12,470,000 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analyst Weigh In

Separately, Berenberg Bank upgraded shares of Conduit Pharmaceuticals to a “strong-buy” rating in a research note on Friday, July 26th.

Conduit Pharmaceuticals Stock Performance

Shares of CDT remained flat at $0.13 on Friday. The company had a trading volume of 2,803,346 shares, compared to its average volume of 4,627,282. The business has a 50-day moving average price of $0.20 and a 200 day moving average price of $1.85. Conduit Pharmaceuticals has a one year low of $0.11 and a one year high of $25.00.

Conduit Pharmaceuticals (NASDAQ:CDT) last announced its earnings results on Monday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.